BACKGROUND: Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFC) are related disorders associated with disrupted RAS/RAF/MEK/ERK signalling. NS, characterised by facial dysmorphism, congenital heart defects and short stature, is caused by mutations in the genes PTPN11, SOS1, KRAS and RAF1. CFC is distinguished from NS by the presence of ectodermal abnormalities and more severe mental retardation in addition to the NS phenotype. The genetic aetiology of CFC was recently assigned to four genes: BRAF, KRAS, MEK1 and MEK2. METHODS: A comprehensive mutation analysis of BRAF, KRAS, MEK1, MEK2 and SOS1 in 31 unrelated patients without mutations in PTPN11 is presented. RESULTS: Mutations were identified in seven patients with CFC (two in BRAF, one in KRAS, one in MEK1, two in MEK2 and one in SOS1). Two mutations were novel: MEK1 E203Q and MEK2 F57L. The SOS1 E433K mutation, identified in a patient diagnosed with CFC, has previously been reported in patients with NS. In one patient with NS, we also identified a mutation, BRAF K499E, that has previously been reported in patients with CFC. We thus suggest involvement of BRAF in the pathogenesis of NS also. CONCLUSIONS: Taken together, our results indicate that the molecular and clinical overlap between CFC and NS is more complex than previously suggested and that the syndromes might even represent allelic disorders. Furthermore, we suggest that the diagnosis should be refined to, for example, NS-PTPN11-associated or CFC-BRAF-associated syndromes after the genetic defect has been established, as this may affect the prognosis and treatment of the patients.
BACKGROUND:Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFC) are related disorders associated with disrupted RAS/RAF/MEK/ERK signalling. NS, characterised by facial dysmorphism, congenital heart defects and short stature, is caused by mutations in the genes PTPN11, SOS1, KRAS and RAF1. CFC is distinguished from NS by the presence of ectodermal abnormalities and more severe mental retardation in addition to the NS phenotype. The genetic aetiology of CFC was recently assigned to four genes: BRAF, KRAS, MEK1 and MEK2. METHODS: A comprehensive mutation analysis of BRAF, KRAS, MEK1, MEK2 and SOS1 in 31 unrelated patients without mutations in PTPN11 is presented. RESULTS: Mutations were identified in seven patients with CFC (two in BRAF, one in KRAS, one in MEK1, two in MEK2 and one in SOS1). Two mutations were novel: MEK1E203Q and MEK2F57L. The SOS1E433K mutation, identified in a patient diagnosed with CFC, has previously been reported in patients with NS. In one patient with NS, we also identified a mutation, BRAFK499E, that has previously been reported in patients with CFC. We thus suggest involvement of BRAF in the pathogenesis of NS also. CONCLUSIONS: Taken together, our results indicate that the molecular and clinical overlap between CFC and NS is more complex than previously suggested and that the syndromes might even represent allelic disorders. Furthermore, we suggest that the diagnosis should be refined to, for example, NS-PTPN11-associated or CFC-BRAF-associated syndromes after the genetic defect has been established, as this may affect the prognosis and treatment of the patients.
Authors: Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker Journal: Am J Med Genet C Semin Med Genet Date: 2011-04-14 Impact factor: 3.908
Authors: Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman Journal: Proc Natl Acad Sci U S A Date: 2017-01-03 Impact factor: 11.205
Authors: Ana Justino; Patrícia Dias; Maria João Pina; Sónia Sousa; Luís Cirnes; Ana Berta Sousa; José Carlos Machado; José Luis Costa Journal: Eur J Hum Genet Date: 2014-06-04 Impact factor: 4.246
Authors: Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Andrew R Grant; Brandon J Cushman; Hélène Cavé; Mitchell W Dillon; Bruce D Gelb; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Marco Tartaglia; Lisa M Vincent; Martin Zenker Journal: Hum Mutat Date: 2018-11 Impact factor: 4.878
Authors: Elizabeth I Pierpont; Susan Ellis Weismer; Amy E Roberts; Erica Tworog-Dube; Mary Ella Pierpont; Nancy J Mendelsohn; Mark S Seidenberg Journal: J Speech Lang Hear Res Date: 2010-06-11 Impact factor: 2.297
Authors: E A Croonen; W Nillesen; C Schrander; M Jongmans; H Scheffer; C Noordam; J M T Draaisma; I van der Burgt; H G Yntema Journal: Mol Syndromol Date: 2013-05-08
Authors: E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg Journal: Genes Brain Behav Date: 2008-12-11 Impact factor: 3.449